AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18788410 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin stimulating agents (ESAs) treatment targeting lower hemoglobin levels (sub-normal level)
Number of subjects: 0
Study 16648977 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled mild hypothermia (32-34 degrees C for 12-24 hours)
Number of subjects: 0
Study 16648977 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not specified)
Number of subjects: 0
Study 12859446 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen (A)
Number of subjects: 10
Study 12859446 — intervention group
Group type: COMPARATOR
Intervention: Experimental diluent (D)
Number of subjects: 10
Study 12859446 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen (A) and Experimental diluent (D)
Number of subjects: 10
Study 10731496 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy sterol esters
Number of subjects: 7
Study 10731496 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-sitostanol ester
Number of subjects: 7
Study 10731496 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 7
Study 9186459 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms intravenous)
Number of subjects: 40
Study 9186459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1586104 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 1200 mg/d
Number of subjects: 711
Study 1586104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 3518121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 3518121 — intervention group
Group type: COMPARATOR
Intervention: Multimodality therapy
Number of subjects: 0
Study 31900959 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily
Number of subjects: 172
Study 31900959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 29738282 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg BM
Number of subjects: 10
Study 29738282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 27091542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-pressure CPAP (FP-CPAP)
Number of subjects: 322
Study 27091542 — intervention group
Group type: COMPARATOR
Intervention: Auto-adjusting CPAP (AutoCPAP)
Number of subjects: 322
Study 24471505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (Gaviscon DA)
Number of subjects: 110
Study 24471505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 22293631 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein 300 mg/d
Number of subjects: 59
Study 22293631 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein 600 mg/d
Number of subjects: 59
Study 22293631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 22293631 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (combined arms)
Number of subjects: 59
Study 20534746 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental choline
Number of subjects: 103
Study 20534746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 17235043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg (loading dose of 840 mg)
Number of subjects: 68
Study 17235043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 1,050 mg
Number of subjects: 68
Study 16240973 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an offer of physician-led prayer
Number of subjects: 137
Study 16240973 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 137
Study 11895166 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (one cup)
Number of subjects: 20
Study 11895166 — intervention group
Group type: COMPARATOR
Intervention: Hot water (one cup)
Number of subjects: 20
Study 10434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 88
Study 10434168 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron 5 mg
Number of subjects: 88
Study 7540758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal artery thrombosis lesions
Number of subjects: 35
Study 7540758 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine death cases (positive controls)
Number of subjects: 35
Study 7540758 — intervention group
Group type: COMPARATOR
Intervention: Normal control cases
Number of subjects: 35
Study 2115045 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 41
Study 2115045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac
Number of subjects: 41
Study 2115045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2115045 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 41
Study 401699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen (2,400 mg/day)
Number of subjects: 40
Study 401699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3,900 mg/day)
Number of subjects: 40
Study 401699 — intervention group
Group type: COMPARATOR
Intervention: Gold induction therapy
Number of subjects: 40
Study 30924190 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Coaching Program
Number of subjects: 132
Study 30924190 — intervention group
Group type: COMPARATOR
Intervention: Health Education Group
Number of subjects: 132
Study 30924190 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 132
Study 28709630 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian New Moves Program (multicomponent intervention aimed at preventing weight-related problems)
Number of subjects: 0
Study 24786933 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccination (TIV)
Number of subjects: 0
Study 23910402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh scent (N = 79)
Number of subjects: 165
Study 23910402 — intervention group
Group type: COMPARATOR
Intervention: Standard environment (N = 86)
Number of subjects: 165
Study 20649451 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive technology with emotionally related narrative
Number of subjects: 84
Study 20649451 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive technology without emotionally related narrative
Number of subjects: 84
Study 20649451 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive technology with emotionally related narrative
Number of subjects: 84
Study 20649451 — intervention group
Group type: COMPARATOR
Intervention: Non-immersive technology without emotionally related narrative
Number of subjects: 84
Study 19966607 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted sigmoidectomy
Number of subjects: 45
Study 19966607 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-facilitated sigmoidectomy
Number of subjects: 45
Study 19966607 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 45
Study 17827352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive anti-malarial treatment (artesunate and sulfadoxine-pyrimethamine)
Number of subjects: 1063
Study 17827352 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1063
Study 15471830 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide therapy with 131I-MIBG (3.7-7.4 GBq, n = 5) or 111In-pentetreotide (7 GBq, n = 15) administered 3 times monthly
Number of subjects: 32
Study 11532549 — intervention group
Group type: EXPERIMENTAL
Intervention: Motionless standing for 15 min
Number of subjects: 23
Study 11532549 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) at 80 degrees for 30 min
Number of subjects: 23
Study 11532549 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal children)
Number of subjects: 23
Study 9760640 — intervention group
Group type: EXPERIMENTAL
Intervention: Feigned malingerers with warning
Number of subjects: 48
Study 9760640 — intervention group
Group type: EXPERIMENTAL
Intervention: Feigned malingerers without warning
Number of subjects: 48
Study 9760640 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 8157852 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% LCT
Number of subjects: 20
Study 8157852 — intervention group
Group type: COMPARATOR
Intervention: 50% LCT/50% MCT
Number of subjects: 20
Study 3149935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 85
Study 3149935 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (V)
Number of subjects: 85
Study 3149935 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (N) + Heparin (H)
Number of subjects: 85
Study 29024080 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty with rapid ventricular pacing (RP)
Number of subjects: 100
Study 29024080 — intervention group
Group type: COMPARATOR
Intervention: Balloon aortic valvuloplasty without rapid ventricular pacing (noRP)
Number of subjects: 100
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram risk score derived from training cohort
Number of subjects: 1323
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 50 years
Number of subjects: 1323
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Past excessive alcohol intake
Number of subjects: 1323
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet count (<100 Giga/mm(3))
Number of subjects: 1323
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet count ([100; 150] Giga/mm(3))
Number of subjects: 1323
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma‐glutamyl transpeptidase above the upper limit of normal
Number of subjects: 1323
Study 27348075 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of a sustained virological response during follow‐up
Number of subjects: 1323
Study 24184249 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day
Number of subjects: 309
Study 24184249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 309
Study 23653901 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Gluma inside (1‐SE)
Number of subjects: 90
Study 23653901 — intervention group
Group type: COMPARATOR
Intervention: Gluma Comfort Bond (2‐ER)
Number of subjects: 90
Study 19364728 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud's condition score (RCS) improvement group
Number of subjects: 162
Study 19364728 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud's condition score (RCS)
Number of subjects: 162
Study 18327721 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccine
Number of subjects: 0
Study 18327721 — intervention group
Group type: EXPERIMENTAL
Intervention: Other interval estimators
Number of subjects: 0
Study 15818640 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus manual therapy
Number of subjects: 350
Study 15818640 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus pulsed shortwave diathermy
Number of subjects: 350
Study 15818640 — intervention group
Group type: COMPARATOR
Intervention: Advice and exercise alone
Number of subjects: 350
Study 12433711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids (SFAs)
Number of subjects: 197
Study 12433711 — intervention group
Group type: EXPERIMENTAL
Intervention: Myristic acid (C14:0)
Number of subjects: 197
Study 12433711 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (C16:0)
Number of subjects: 197
Study 12433711 — intervention group
Group type: EXPERIMENTAL
Intervention: Total polyunsaturated fatty acids (PUFAs) (n-6 and n-3)
Number of subjects: 197
Study 12433711 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual n-3 fatty acids of marine origin (eicosapentaenoic acid (C20:5 n-3) and docosahexaenoic acid (C22:6 n-3))
Number of subjects: 197
Study 12433711 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 197
Study 10487668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) plus HRT
Number of subjects: 428
Study 10487668 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus HRT
Number of subjects: 428
Study 10487668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus HRT
Number of subjects: 428
Study 9019933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 0
Study 9019933 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 0
Study 1886590 — intervention group
Group type: COMPARATOR
Intervention: i.v. 5‐FU alone (Group A)
Number of subjects: 25
Study 1886590 — intervention group
Group type: COMPARATOR
Intervention: i.v. 5‐FU with AT‐II (Group B)
Number of subjects: 25
Study 1886590 — intervention group
Group type: COMPARATOR
Intervention: i.a. 5‐FU alone (Group C)
Number of subjects: 25
Study 1886590 — intervention group
Group type: EXPERIMENTAL
Intervention: i.a. 5‐FU with i.v. AT‐II (Group D)
Number of subjects: 25
Study 1886590 — intervention group
Group type: EXPERIMENTAL
Intervention: i.a. 5‐FU with AT‐II (Group E)
Number of subjects: 25
Study 6620717 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenylephrine (20 microliters of phenylephrine HCL 10%)
Number of subjects: 11
Study 6620717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31467049 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XBJ), every 12 hours for 5 days
Number of subjects: 1800
Study 31467049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study 31467049 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XBJ)
Number of subjects: 1800
Study 29908220 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated quantitative mpMRI-based method for habitat risk scoring (HRS)
Number of subjects: 12
Study 27036408 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) intervention, delivered online, single module, details on dosage and duration not specified.
Number of subjects: 600
Study 24699050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C)
Number of subjects: 349
Study 24699050 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy (international normalized ratio 2‐3)
Number of subjects: 349
Study 24699050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (A+C)
Number of subjects: 349
Study 24699050 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 349
Study 22251528 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week method of S-1 administration
Number of subjects: 146
Study 22251528 — intervention group
Group type: COMPARATOR
Intervention: 4-week method of S-1 administration
Number of subjects: 146
Study 19818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise immediately prior to vaccination
Number of subjects: 156
Study 19818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise 6 hours prior to vaccination
Number of subjects: 156
Study 19818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise 48 hours prior to vaccination
Number of subjects: 156
Study 19818846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 156
Study 17116123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rabeprazole 20 mg
Number of subjects: 38
Study 17116123 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg
Number of subjects: 38
Study 16491579 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber meal at 2500 m
Number of subjects: 16
Study 16491579 — intervention group
Group type: COMPARATOR
Intervention: Low fiber meal at 2500 m
Number of subjects: 16
Study 14605051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administered within 4 hours (group 1)
Number of subjects: 409
Study 14605051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administered between 4 to 8 hours (group 2)
Number of subjects: 409
Study 14605051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administered after 8 hours (group 3)
Number of subjects: 409
Study 14605051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 409
Study 10761530 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated G-CSF (lenograstim, 2 micrograms/kg)
Number of subjects: 10
Study 10761530 — intervention group
Group type: COMPARATOR
Intervention: Mutated G-CSF (nartograstim, 1 microgram/kg)
Number of subjects: 10
Study 8881327 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations based on categorization of concepts in reasoning problems
Number of subjects: 0
Study 8881327 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual knowledge influence
Number of subjects: 0
Study 1579299 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of 2% clindamycin vaginal cream daily for 7 days
Number of subjects: 48
Study 1579299 — intervention group
Group type: COMPARATOR
Intervention: 500 mg metronidazole oral tablets twice a day for 7 days
Number of subjects: 48
Study 6436861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine (4 X 20 mg/day)
Number of subjects: 10
Study 6436861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromvincamine (4 X 20 mg/day)
Number of subjects: 10
Study 6436861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30682104 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS score
Number of subjects: 8204
Study 30682104 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 8204
Study 30682104 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS score
Number of subjects: 8204
Study 30480830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fashion warning labels
Number of subjects: 118
Study 30480830 — intervention group
Group type: COMPARATOR
Intervention: No warning labels
Number of subjects: 118
Study 30480830 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to warning labels
Number of subjects: 118
Study 27367303 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured skin self-examination (SSE) skills training intervention
Number of subjects: 494
Study 27367303 — intervention group
Group type: COMPARATOR
Intervention: Customary care (control group)
Number of subjects: 494
Study 25250626 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of baseline dietary glycemic index (GI)
Number of subjects: 3583
Study 25250626 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly updated dietary glycemic index (GI)
Number of subjects: 3583
Study 25250626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL)
Number of subjects: 3583
Study 23059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etch adhesive (Clearfil Protect Bond) used in group 6
Number of subjects: 49
Study 23059577 — intervention group
Group type: COMPARATOR
Intervention: Conventional cavity conditioner (GC cavity conditioner) used in group 7
Number of subjects: 49
Study 23059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse adhesive (Optibond FL) used in group 1
Number of subjects: 49
Study 23059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive (One Step Plus) used in group 2
Number of subjects: 49
Study 23059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (APX) used in groups 1, 2, and 3
Number of subjects: 49
Study 23059577 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer (Fuji II LC) used in groups 4, 5, 6, and 7
Number of subjects: 49
Study 19888978 — intervention group
Group type: EXPERIMENTAL
Intervention: High EZH2 expression (>1.0%)
Number of subjects: 86
Study 19888978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low p27(kip1) expression (<90%)
Number of subjects: 86
Study 19888978 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant disease presence
Number of subjects: 86
Study 17490965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trace element (TE) supplementation (copper, selenium, zinc) for 14-21 days
Number of subjects: 21
Study 16202731 — intervention group
Group type: COMPARATOR
Intervention: HMR 3339 50 mg
Number of subjects: 118
Study 16202731 — intervention group
Group type: COMPARATOR
Intervention: HMR 3339 2.5 mg
Number of subjects: 118
Study 16202731 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 118
Study 11782615 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b and ribavirin (5 MU/d for 4 weeks, 5 MU three times weekly for 8 weeks, then 3 MU three times weekly for 36 weeks)
Number of subjects: 107
Study 11782615 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose interferon alfa-2b and ribavirin (for 48 weeks)
Number of subjects: 107
Study 10524468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine and bupivacaine
Number of subjects: 20
Study 10524468 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study 7742124 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital luminescence radiography (DLR)
Number of subjects: 326
Study 7742124 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 326
Study 7742124 — intervention group
Group type: EXPERIMENTAL
Intervention: High spatial frequency enhancement in DLR
Number of subjects: 326
Study 1952438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg given rectally every 4 h for three doses)
Number of subjects: 30
Study 1952438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1952438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30
Study 7037791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (constant, variable dose infusion)
Number of subjects: 18
Study 7037791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroprusside)
Number of subjects: 18
Study 30871907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone fixation technique using an interference screw for gracilis tendon
Number of subjects: 60
Study 30871907 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue fixation technique looping the gracilis tendon around the adductor magnus tendon
Number of subjects: 60